Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Metastatic Solid Tumors 2Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer 1Recurrence 1Prostate Cancer Patients Undergoing Radical Prostatectomy 1Neoadjuvant Treatment for Locally Advanced Cervical Cancer 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 243Carboplatin 211Pemetrexed 177Cisplatin 131Paclitaxel 113Nivolumab 101Docetaxel 87osimertinib 85durvalumab 78Specimen Handling 56atezolizumab 55Gemcitabine 52Drug Therapy 52Magnetic Resonance Spectroscopy 50Radiosurgery 48Radiotherapy 47Ipilimumab 41130-nm albumin-bound paclitaxel 39cemiplimab 38Bevacizumab 34Cetuximab 30tislelizumab 29amivantamab 22Taxes 22Platinum Compounds 20Blood Specimen Collection 20Immunotherapy 18Immune Checkpoint Inhibitors 18Radiation 17Erlotinib Hydrochloride 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × Infusions, Intravenous × 1 year × Clear all
NCT05894889 2025-07-23

Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC

Peking University

Phase 2 Active not recruiting
70 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡